MBL Wealth LLC Purchases 5,316 Shares of Merck & Co., Inc. $MRK

MBL Wealth LLC increased its position in Merck & Co., Inc. (NYSE:MRK) by 75.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 12,356 shares of the company’s stock after acquiring an additional 5,316 shares during the quarter. MBL Wealth LLC’s holdings in Merck & Co., Inc. were worth $1,301,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of MRK. Payne Capital LLC increased its holdings in shares of Merck & Co., Inc. by 0.9% during the 4th quarter. Payne Capital LLC now owns 10,637 shares of the company’s stock worth $1,120,000 after purchasing an additional 97 shares during the period. Abound Wealth Management increased its holdings in shares of Merck & Co., Inc. by 6.8% during the 4th quarter. Abound Wealth Management now owns 1,554 shares of the company’s stock worth $164,000 after purchasing an additional 99 shares during the period. Mattern Wealth Management LLC increased its holdings in shares of Merck & Co., Inc. by 1.7% during the 4th quarter. Mattern Wealth Management LLC now owns 6,033 shares of the company’s stock worth $635,000 after purchasing an additional 100 shares during the period. Jmac Enterprises LLC increased its holdings in shares of Merck & Co., Inc. by 1.6% during the 4th quarter. Jmac Enterprises LLC now owns 6,616 shares of the company’s stock worth $696,000 after purchasing an additional 103 shares during the period. Finally, Pine Haven Investment Counsel Inc increased its holdings in shares of Merck & Co., Inc. by 0.7% during the 4th quarter. Pine Haven Investment Counsel Inc now owns 14,137 shares of the company’s stock worth $1,488,000 after purchasing an additional 105 shares during the period. Institutional investors own 76.07% of the company’s stock.

Insider Activity at Merck & Co., Inc.

In other news, EVP Jennifer Zachary sold 121,573 shares of the company’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $119.15, for a total transaction of $14,485,422.95. Following the transaction, the executive vice president directly owned 68,916 shares in the company, valued at approximately $8,211,341.40. This represents a 63.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Caroline Litchfield sold 41,997 shares of the company’s stock in a transaction that occurred on Wednesday, February 4th. The stock was sold at an average price of $119.61, for a total transaction of $5,023,261.17. Following the transaction, the chief financial officer owned 90,192 shares in the company, valued at $10,787,865.12. The trade was a 31.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 320,176 shares of company stock valued at $38,281,735 in the last three months. 0.09% of the stock is currently owned by corporate insiders.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: JPMorgan raised its price target to $135 and kept an Overweight rating, signaling analyst confidence in MRK’s outlook and providing near-term upside support. Benzinga: JPMorgan raises price target
• Positive Sentiment: Quarterly strength is being highlighted by investors and funds (TCW note): strong Q4 results and continuing revenue/earnings momentum bolster the company’s fundamentals and dividend/total-return story. Strong Results Lifted Merck & Co (MRK) in Q4
• Positive Sentiment: Merck’s planned acquisition of Terns Pharmaceuticals adds early- and mid-stage oncology assets, helping replenish the pipeline ahead of Keytruda patent pressures — a strategic, long-term positive for oncology exposure. Merck’s Terns Deal Targets Cancer Pipeline And Keytruda Patent Risks
• Neutral Sentiment: Merck formally commenced a cash tender offer for Terns (deal mechanics underway); closing is expected in Q2 2026 subject to conditions — procedural step that keeps the acquisition on track. Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.
• Neutral Sentiment: Broader healthcare/M&A coverage notes an industry-wide pickup in transactions as peers bolster pipelines — a contextual tailwind but not company-specific. Pharma, Biotech Giants Ramp Up M&A in Q1
• Neutral Sentiment: General analyst/market commentary pieces and related biotech updates reference Merck as a defensive/dividend name, supporting its investor appeal but not changing near-term fundamentals. Analysts Offer Insights on Healthcare Companies: Merck (MRK)
• Negative Sentiment: Merck reportedly lowered its offer price for Terns after reviewing trial data, which may signal diligence concerns about the target’s assets and has likely created near‑term investor uncertainty about deal value/benefit. Merck Lowered Terns Pharmaceuticals Offer Price
• Negative Sentiment: Short-term price weakness: coverage notes MRK shares declined while the broader market improved, suggesting profit-taking or deal-related jitters are weighing on the stock today. Merck (MRK) Stock Declines While Market Improves
• Negative Sentiment: Cautionary pieces ask whether defensive names like Merck are overbought after recent gains, which can pressure the stock if investors rotate out of healthcare. Is It Too Late to Buy Costco or Merck?

Analyst Ratings Changes

MRK has been the topic of several research reports. Wall Street Zen upgraded shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a report on Saturday, March 28th. Royal Bank Of Canada restated an “outperform” rating and set a $142.00 price objective on shares of Merck & Co., Inc. in a report on Monday, March 30th. Wolfe Research upgraded shares of Merck & Co., Inc. from a “peer perform” rating to an “outperform” rating and set a $135.00 price objective on the stock in a report on Thursday, January 8th. Guggenheim boosted their price objective on shares of Merck & Co., Inc. from $122.00 to $140.00 and gave the stock a “buy” rating in a report on Friday, February 6th. Finally, TD Cowen boosted their price objective on shares of Merck & Co., Inc. from $100.00 to $120.00 and gave the stock a “hold” rating in a report on Tuesday, January 20th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and seven have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $127.59.

Merck & Co., Inc. Price Performance

Shares of Merck & Co., Inc. stock opened at $118.91 on Wednesday. The company has a current ratio of 1.54, a quick ratio of 1.30 and a debt-to-equity ratio of 0.89. The stock has a market capitalization of $293.98 billion, a price-to-earnings ratio of 16.33, a P/E/G ratio of 2.44 and a beta of 0.26. Merck & Co., Inc. has a 1-year low of $73.31 and a 1-year high of $125.14. The firm’s 50-day moving average price is $118.21 and its two-hundred day moving average price is $103.93.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Tuesday, February 3rd. The company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $2.01 by $0.03. The firm had revenue of $16.40 billion for the quarter, compared to analysts’ expectations of $16.19 billion. Merck & Co., Inc. had a net margin of 28.08% and a return on equity of 44.57%. The company’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.72 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. On average, equities analysts predict that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, April 7th. Stockholders of record on Monday, March 16th were given a dividend of $0.85 per share. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date was Monday, March 16th. Merck & Co., Inc.’s dividend payout ratio is presently 46.70%.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.